{
  "entity_id": "B-002535",
  "folder": "Advisory-Committee-on-Biologicals",
  "name": "Advisory Committee on Biologicals",
  "type": "Statutory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "https://www.tga.gov.au/about-tga/advisory-bodies-and-committees/advisory-committee-biologicals-acb",
  "data_status": "partial",
  "completeness": {
    "has_strategy_brief": false,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": false,
    "has_kpi_results": false,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_global_initiatives_structured": false,
    "n_global_initiatives": 0,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 3,
    "n_kpi_targets": 0,
    "n_kpi_results": 0,
    "n_outcomes": 0,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "medium",
    "summary": "",
    "official_site_url": "https://www.tga.gov.au/about-tga/advisory-bodies-and-committees/advisory-committee-biologicals-acb",
    "source_documents": [],
    "purpose": null,
    "vision": null,
    "strategic_priorities": [],
    "values": [],
    "outcomes": [],
    "performance_measures": [],
    "document_alignment_terms": {
      "must_support": [],
      "watch_terms": [],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "Structured strategy exists but is incomplete."
  },
  "global_initiatives": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": null,
    "purposes_source_page": null,
    "how_we_deliver": null,
    "how_we_deliver_source_page": null,
    "government_priorities": [],
    "outcomes": [],
    "values": [],
    "values_framework_name": null,
    "kpi_targets_2025_26": [],
    "kpi_results_2024_25": [],
    "_source_urls": {
      "annual_report_url": "",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Regulation & Policy",
      "scale": "small",
      "title": "Regulatory burden scan for forms, guidance, and reporting",
      "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Regulation & Policy",
      "scale": "large",
      "title": "Adaptive regulation program with live feedback loops",
      "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "In addition to responding to high-risk allegations of non-compliance regarding these products we will:\nengage with industry regarding its regulatory obligations for the advertising of associated therapeutic goods\nprovide community education regarding the risks associated with the use of unapproved therapeutic goods as issues and trends emerge or are foreseen\ngather and use intelligence to identify higher-risk trends and products\ncontinue to use compliance projects to address these trends and products as identified\ncontinue to target advertising of unapproved products on digital platforms.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/announcements-index__12.html (https://www.tga.gov.au/safety/compliance-and-enforcement/compliance-management-enforcement/import-advertising-and-supply-compliance-priorities-2023-25)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "In addition to responding to high-risk allegations of non-compliance regarding these products we will:\nengage with industry regarding its regulatory obligations for the advertising of associated therapeutic goods\nprovide community education regarding the risks associated with the use of unapproved therapeutic goods as issues and trends emerge or are foreseen\ngather and use intelligence to identify higher-risk trends and products\ncontinue to use compliance projects to address these trends and products as identified\ncontinue to target advertising of unapproved products on digital platforms.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/announcements-index__12.html (https://www.tga.gov.au/safety/compliance-and-enforcement/compliance-management-enforcement/import-advertising-and-supply-compliance-priorities-2023-25)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Citizen Participation",
      "scale": "small",
      "title": "Consultation feedback summaries with response tracking",
      "idea": "Summarise consultation submissions by theme and publish what changed in response.",
      "quote": "2016\nMeeting 8, 17 November 2016\nTopics discussed included -\nvarious GMP Clearance Issues including the development of a new e-form and associated workflow\nthe consultation process for revisions to the PIC/S Guide\nthe GMP standard for medicinal cannabis\nthe likelihood of impact of the Medicines and Medical Devices Review (MMDR) reforms on MQB\ncurrent and future updates to the PIC/S Guide\nconsultation on the PIC/S gap analysis: Version 9 vs Version 13\nconsultation on an ISO Standard gap analysis - ISO14644:2015 (Part 1 and 2) Cleanrooms and associated controlled environments\nPIC/S Guidance on Data Integrity\nAustralian implications for European API inspection requirements\nTGA hosting of an API PIC/S Expert Circle Meeting\nstatus of the revised Uniform Recall Procedure for Therapeutic Goods",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "pages/taskforces-index__05.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/tga-industry-working-group-good-manufacturing-practice-gmp-tiwgg/tiwgg-meeting-summaries)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Citizen Participation",
      "scale": "large",
      "title": "Always-on policy participation platform",
      "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.",
      "quote": "2016\nMeeting 8, 17 November 2016\nTopics discussed included -\nvarious GMP Clearance Issues including the development of a new e-form and associated workflow\nthe consultation process for revisions to the PIC/S Guide\nthe GMP standard for medicinal cannabis\nthe likelihood of impact of the Medicines and Medical Devices Review (MMDR) reforms on MQB\ncurrent and future updates to the PIC/S Guide\nconsultation on the PIC/S gap analysis: Version 9 vs Version 13\nconsultation on an ISO Standard gap analysis - ISO14644:2015 (Part 1 and 2) Cleanrooms and associated controlled environments\nPIC/S Guidance on Data Integrity\nAustralian implications for European API inspection requirements\nTGA hosting of an API PIC/S Expert Circle Meeting\nstatus of the revised Uniform Recall Procedure for Therapeutic Goods",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "pages/taskforces-index__05.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/tga-industry-working-group-good-manufacturing-practice-gmp-tiwgg/tiwgg-meeting-summaries)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Staff Productivity",
      "scale": "small",
      "title": "Reusable briefing and summary assistant for internal documents",
      "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.",
      "quote": "Overview of the therapeutic goods referred for advice\nAt this meeting, the committee's advice was sought on one issue:\nProposed changes to the deferral of blood donors in relation to variant CJD geographical risk.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "pages/announcements-index.html (https://www.tga.gov.au/resources/publication/meeting-statements/acb-meeting-statement-meeting-18-24-february-2022)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Staff Productivity",
      "scale": "large",
      "title": "Department-wide knowledge and briefing platform",
      "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.",
      "quote": "Overview of the therapeutic goods referred for advice\nAt this meeting, the committee's advice was sought on one issue:\nProposed changes to the deferral of blood donors in relation to variant CJD geographical risk.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "pages/announcements-index.html (https://www.tga.gov.au/resources/publication/meeting-statements/acb-meeting-statement-meeting-18-24-february-2022)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Case Processing",
      "scale": "small",
      "title": "Triage queue for stuck or ageing cases",
      "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.",
      "quote": "The working group continued discussions on the TGA risk assessment framework for breast implants, including how to enhance the framework’s adaptability to include a broader spectrum of topics on breast implant-related issues.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "pages/taskforces-index__09.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/breast-implant-expert-and-consumer-working-groups)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "category": "Case Processing",
      "scale": "large",
      "title": "End-to-end case processing redesign",
      "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.",
      "quote": "The working group continued discussions on the TGA risk assessment framework for breast implants, including how to enhance the framework’s adaptability to include a broader spectrum of topics on breast implant-related issues.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "pages/taskforces-index__09.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/breast-implant-expert-and-consumer-working-groups)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "other-pdfs",
      "year": "2023",
      "url": "https://www.tga.gov.au/sites/default/files/2023-08/acb-meeting-statement-meeting-18-24-february-2022.pdf",
      "file": "other-pdfs/acb-meeting-statement-meeting-18-24-february-2022.pdf",
      "bytes": 34422,
      "link_text": "Download ACB meeting statement, Meeting 18, 24 February 2022 as PDF"
    },
    {
      "category": "other-pdfs",
      "year": "2024",
      "url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf",
      "file": "other-pdfs/medical-devices-consumer-working-group-terms-of-reference.pdf",
      "bytes": 332294,
      "link_text": "Medical Devices Consumer Working Group: Terms of Reference"
    },
    {
      "category": "other-pdfs",
      "year": "2023",
      "url": "https://www.tga.gov.au/sites/default/files/2023-05/patient-information-materials-for-medical-implants-a-fact-sheet-for-consumers.PDF",
      "file": "other-pdfs/patient-information-materials-for-medical-implants-a-fact-sheet-for-consumers.pdf",
      "bytes": 1646717,
      "link_text": "Patient information materials for medical implants: a fact sheet for consumers"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-14T02:12:05+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Advisory-Committee-on-Biologicals",
      "annual_report": {
        "file": null,
        "url": "",
        "year": null
      },
      "corporate_plan": {
        "file": "other-pdfs\\acb-meeting-statement-meeting-18-24-february-2022.txt",
        "url": "https://www.tga.gov.au/sites/default/files/2023-08/acb-meeting-statement-meeting-18-24-february-2022.pdf",
        "year": "acb-meeting-statement-meeting-18-24-february-2022"
      },
      "usage": {
        "input_tokens": 1482,
        "output_tokens": 155,
        "total_tokens": 1637,
        "model": "nova-micro"
      },
      "cost_usd": 0.00007357,
      "elapsed_seconds": 1.29,
      "generated_at": "2026-05-13T05:15:27+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-002535",
      "entity_name": "Advisory Committee on Biologicals",
      "folder_name": "Advisory-Committee-on-Biologicals",
      "generated_at": "2026-05-09T23:05:35.630188+00:00",
      "idea_count": 12,
      "markdown": "ideas/Advisory-Committee-on-Biologicals_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Advisory-Committee-on-Biologicals_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}